CCR3: Containing prostate cancer - A drug-repositionning approach integrating obesity factor

DESCRIPTION

A drug-repositionning approach integrating obesity factor
Prostate cancer (Pca): local and metastasis dissemination at stake

85% of patients with localized Pca have an overall survival > 10 years

But risk of extraprostatic disease remains high (30-60%) and bone metastasis is the most common form (70-90% of cases)

Prognosis of metastasized Pca is low (survival < 2 years) 

Preventing/slowing  down the spread of Pca outside the capsule and especially to the bone is a major goal of treatment

APPLICATIONS

Prostate cancer treatment, especially in a context of obesity or metabolic disease